Pharma BD Deal Intelligence

Sanofi SA / Genzyme Corporation

2011 · Acquisition/Merger · $20.1B · Complete

Announcement Sentiment

Positive

Outcome Score

Worked — the deal delivered on its rationale.

Sanofi-aventis acquired Genzyme Corporation for approximately $20.1 billion ($74.00 per share in cash plus one Contingent Value Right per share), gaining a leading rare disease portfolio including Cerezyme, Fabrazyme, and the multiple sclerosis candidate Lemtrada (alemtuzumab).

Key facts

Announced Feb 16, 2011
Closed Apr 08, 2011
Deal value $20.1B
Deal type Acquisition/Merger
Therapeutic area Metabolic, Nephrology, Neurology, Oncology, Rare Disease
Indications Gaucher Disease, Fabry Disease, Multiple Sclerosis, Pompe Disease
Key assets Cerezyme (imiglucerase), Fabrazyme (agalsidase beta), Lemtrada (alemtuzumab), Myozyme (alglucosidase alfa), Lumizyme (alglucosidase alfa), Thyrogen (thyrotropin alfa), Synvisc (hylan G-F 20)
Mechanism Enzyme replacement therapy, Anti-CD52 monoclonal antibody

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals